Search Results - "Kulkarni, Pandurang M"

Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study by Siris, Ethel S, Harris, Steven T, Eastell, Richard, Zanchetta, Jose R, Goemaere, Stefan, Diez‐Perez, Adolfo, Stock, John L, Song, Jingli, Qu, Yongming, Kulkarni, Pandurang M, Siddhanti, Suresh R, Wong, Mayme, Cummings, Steven R

“…In the CORE breast cancer trial of 4011 women continuing from MORE, the incidence of nonvertebral fractures at 8 years was similar between placebo and…”
Get full text

Essential team science skills for biostatisticians on collaborative research teams by Slade, Emily, Brearley, Ann M, Coles, Adrian, Hayat, Matthew J, Kulkarni, Pandurang M, Nowacki, Amy S, Oster, Robert A, Posner, Michael A, Samsa, Gregory, Spratt, Heidi, Troy, Jesse, Pomann, Gina-Maria

“…Despite the critical role that quantitative scientists play in biomedical research, graduate programs in quantitative fields often focus on technical and…”
Get full text

Risk‐Benefit Profile for Raloxifene: 4‐Year Data From the Multiple Outcomes of Raloxifene Evaluation (MORE) Randomized Trial by Barrett‐Connor, Elizabeth, Cauley, Jane A, Kulkarni, Pandurang M, Sashegyi, Andreas, Cox, David A, Geiger, Mary Jane

“…Posthoc analysis of the MORE osteoporosis treatment trial assessed risk‐benefit profile of raloxifene in 7705 postmenopausal women. A major disease outcomes…”
Get full text

The Onset of Inhibition of Platelet Aggregation With Prasugrel Compared With Clopidogrel Loading Doses Using Gatekeeping Analysis of Integrated Clinical Pharmacology Data by Zhu, Baojin, Effron, Mark B, Kulkarni, Pandurang M, Li, Ying G, Jakubowski, Joseph A, Miller, Debra L, Baker, Brian A, Luo, Junxiang, Small, David S, Winters, Kenneth J

“…The purpose of this analysis was to determine the time by which a prasugrel 60-mg loading dose (LD) achieved significantly greater inhibition of platelet…”
Get full text

Medication Nonadherence and Treatment Outcome in Patients With Schizophrenia or Schizoaffective Disorder With Suboptimal Prior Response by LINDENMAYER, Jean-Pierre, LIU-SEIFERT, Hong, CITROME, Leslie, VOLAVKA, Jan, KULKARNI, Pandurang M, KINON, Bruce J, STAUFFER, Virginia, EDWARDS, Sara E, LEI CHEN, ADAMS, David H, ASCHER-SVANUM, Haya, BUCKLEY, Peter F

“…To examine the impact of medication nonadherence on treatment outcome in schizophrenia and potential risk factors for nonadherence. A post hoc analysis of a…”
Get full text

Modeling the impact of preplanned dose titration on delayed response by Qu, Yongming, Liu, Zhuqing, Fu, Haoda, Sethuraman, Shanthi, Kulkarni, Pandurang M.

“…Dose titration becomes more and more common in improving drug tolerability as well as determining individualized treatment doses, thereby maximizing the…”
Get full text

Extending the classification approach for comparing two active treatment arms to binary and time-to-event outcomes by Liu, Jingyi, Qu, Yongming, Kulkarni, Pandurang M.

“…For regulatory purposes, in a trial comparing two active treatments, a hypothesis such as noninferiority or superiority must be prespecified even when there is…”
Get full text

Sensitivity in statistical evaluation of biomarkers by Li, Wen, Qu, Yongming, Kulkarni, Pandurang M.

“…In clinical research and practice, biomarkers help in understanding disease progression and are useful when monitoring patients and making treatment decisions…”
Get full text

Joint modeling of progression-free survival and overall survival by a Bayesian normal induced copula estimation model by Fu, Haoda, Wang, Yanping, Liu, Jingyi, Kulkarni, Pandurang M., Melemed, Allen S.

“…In cancer clinical trials, in addition to time to death (i.e., overall survival), progression‐related measurements such as progression‐free survival and time…”
Get full text

A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis by Body, Jean-Jacques, Gaich, Gregory A., Scheele, Wim H., Kulkarni, Pandurang M., Miller, Paul D., Peretz, Anne, Dore, Robin K., Correa-Rotter, Ricardo, Papaioannou, Alexandra, Cumming, David C., Hodsman, Anthony B.

“…Teriparatide (rDNA origin) injection [recombinant human PTH (1–34)] stimulates bone formation, increases bone mineral density (BMD), and restores bone…”
Get full text

Nonparametric covariate adjustment in estimating hazard ratios by Jiang, Honghua, Kulkarni, Pandurang M, Wang, Yanping, Mallinckrodt, Craig H

“…In randomized clinical trials with time‐to‐event outcomes, the hazard ratio is commonly used to quantify the treatment effect relative to a control. The Cox…”
Get full text

To adjust or not to adjust for baseline when analyzing repeated binary responses? The case of complete data when treatment comparison at study end is of interest by Jiang, Honghua, Kulkarni, Pandurang M., Mallinckrodt, Craig H., Shurzinske, Linda, Molenberghs, Geert, Lipkovich, Ilya

“…The benefits of adjusting for baseline covariates are not as straightforward with repeated binary responses as with continuous response variables. Therefore,…”
Get full text

Comparative effects of raloxifene and alendronate on fracture outcomes in postmenopausal women with low bone mass by Recker, Robert R, Kendler, David, Recknor, Christopher P, Rooney, Theodore W, Lewiecki, E. Michael, Utian, Wulf H, Cauley, Jane A, Lorraine, Joanne, Qu, Yongming, Kulkarni, Pandurang M, Gaich, Carol L, Wong, Mayme, Plouffe, Leo, Stock, John L

“…Abstract The double-blind, randomized raloxifene alendronate comparison trial was the first study designed to compare two osteoporosis therapies head-to-head…”
Get full text

Efficacy and safety of pemetrexed in elderly cancer patients: Results of an integrated analysis by Kulkarni, Pandurang M, Chen, Ruqin, Anand, Taruna, Monberg, Matthew J, Obasaju, Coleman K

“…Abstract Purpose To analyze pemetrexed in elderly patients (≥65 years) based on data collected in three randomized, phase III registration trials. Methods…”
Get full text

Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder by Zhu, Baojin, Kulkarni, Pandurang M, Stensland, Michael D., Ascher-Svanum, Haya

“…ABSTRACT Objective: Atypical antipsychotics are playing an increasing role in the treatment of bipolar disorder. The objective of this study was to assess the…”
Get full text

Estimating the response rate in the presence of measurement error by Qu, Yongming, Kulkarni, Pandurang M., Sanger, Todd M.

“…In clinical research, it is often of interest to estimate the response rate (i.e. the proportion of subjects who achieve a clinically meaningful threshold) for…”
Get full text

Comparison of Fracture, Cardiovascular Event, and Breast Cancer Rates at 3 Years in Postmenopausal Women with Osteoporosis by Silverman, Stuart L., Delmas, Pierre D., Kulkarni, Pandurang M., Stock, John L., Wong, Mayme, Plouffe Jr, Leo

“…Objectives: To compare event rates for osteoporotic fractures, cardiovascular events, and breast cancer in postmenopausal women with osteoporosis. Design: A…”
Get full text

Vascular events in the Multiple Outcomes of Raloxifene Evaluation (MORE) trial: incidence, patient characteristics, and effect of raloxifene by Duvernoy, Claire S, Kulkarni, Pandurang M, Dowsett, Sherie A, Keech, Cheryl A

“…OBJECTIVE:To determine the incidence of arterial and venous thromboembolic (VTE) events, to determine the effect of raloxifene on the incidence of combined…”
Get full text

Raloxifene reduces risk of vertebral fractures and breast cancer in postmenopausal women regardless of prior hormone therapy by Johnell, Olof, Cauley, Jane A, Kulkarni, Pandurang M, Wong, Mayme, Stock, John L

Get full text

Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia by Insull, William, Davidson, Michael H., Kulkarni, Pandurang M., Siddhanti, Suresh, Ciaccia, Angelina V., Keech, Cheryl A.

“…Raloxifene and low-dose simvastatin can each reduce low-density lipoprotein (LDL) cholesterol without affecting high-density lipoprotein (HDL) cholesterol and…”
Get full text